Literature DB >> 8916872

Significant influence of accompanying chronic hepatitis status on recurrence of hepatocellular carcinoma after hepatectomy. Result of multivariate analysis.

S Ko1, Y Nakajima, H Kanehiro, M Hisanaga, Y Aomatsu, T Kin, K Yagura, T Ohyama, K Nishio, K Ohashi, M Sho, T Yamada, H Nakano.   

Abstract

OBJECTIVE: The aim of this study was to evaluate the correlation between the histologic status of accompanying chronic hepatitis and the recurrence rate of hepatocellular carcinoma (HCC) after hepatectomy by multivariate analysis. SUMMARY BACKGROUND DATA: Recent studies have suggested that a considerable number of intrahepatic recurrence of HCC after hepatectomy might be the results of metachronous multicentric hepatocarcinogenesis. The authors hypothesized that the incidence of recurrence due to metachronous multicentric hepatocarcinogenesis would depend on the histologic status of accompanying chronic viral liver disease, which is a main promoter of HCC.
METHODS: One hundred ten patients with HCC who underwent curative resection were studied. Histologic status of accompanying chronic hepatitis was classified into the three categories: 1) normal liver or chronic persistent hepatitis (CPH, n = 13), 2) chronic aggressive hepatitis (CAH, n = 50), and 3) liver cirrhosis (LC, n = 47).
RESULTS: The Cox multivariate proportional hazard model showed that the accompanying chronic viral hepatitis status (p = 0.0133), extent of hepatectomy (p = 0.0078), and number of tumors (p = 0.0475) were significantly predictive variables for recurrence-free survival. By the log-rank test, recurrence-free survival rate in patients with CPH was significantly higher than those in patients with CAH (p = 0.0005) and LC (p = 0.0075). Patients with CAH had the lowest recurrence-free survival rate (vs. LC, p = 0.028).
CONCLUSIONS: The results of this study indicated the significant influence of histologic activity of hepatitis on recurrence of HCC. This might support the concept of significant contribution of multicentric hepatocarcinogenesis to recurrence of HCC after hepatectomy.

Entities:  

Mesh:

Year:  1996        PMID: 8916872      PMCID: PMC1235434          DOI: 10.1097/00000658-199611000-00001

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  22 in total

1.  Liver carcinomas induced in rats by single administration of dimethylnitrosamine after partial hepatectomy.

Authors:  V M Craddock
Journal:  J Natl Cancer Inst       Date:  1971-10       Impact factor: 13.506

2.  A classification of chronic hepatitis.

Authors:  J De Groote; V J Desmet; P Gedigk; G Korb; H Popper; H Poulsen; P J Scheuer; M Schmid; H Thaler; E Uehlinger
Journal:  Lancet       Date:  1968-09-14       Impact factor: 79.321

3.  Is high AgNOR quantity in hepatocytes associated with increased risk of hepatocellular carcinoma in chronic liver disease?

Authors:  M Derenzini; D Trerè; F Oliveri; E David; P Colombatto; F Bonino; M R Brunetto
Journal:  J Clin Pathol       Date:  1993-08       Impact factor: 3.411

Review 4.  Classification of chronic hepatitis: diagnosis, grading and staging.

Authors:  V J Desmet; M Gerber; J H Hoofnagle; M Manns; P J Scheuer
Journal:  Hepatology       Date:  1994-06       Impact factor: 17.425

5.  Recurrence of hepatocellular carcinoma in the liver remnant after hepatic resection.

Authors:  K Ouchi; S Matsubara; K Fukuhara; T Tominaga; S Matsuno
Journal:  Am J Surg       Date:  1993-09       Impact factor: 2.565

6.  Significance of hepatocellular proliferation in the development of hepatocellular carcinoma from anti-hepatitis C virus-positive cirrhotic patients.

Authors:  K Tarao; S Ohkawa; A Shimizu; M Harada; Y Nakamura; Y Ito; S Tamai; H Hoshino; T Inoue; M Kanisawa
Journal:  Cancer       Date:  1994-02-15       Impact factor: 6.860

7.  Influence of coexisting cirrhosis on long-term prognosis after surgery in patients with hepatocellular carcinoma.

Authors:  Y Sasaki; S Imaoka; S Masutani; I Ohashi; O Ishikawa; H Koyama; T Iwanaga
Journal:  Surgery       Date:  1992-09       Impact factor: 3.982

8.  Liver resection for hepatocellular carcinoma. Results of 229 consecutive patients during 11 years.

Authors:  N Nagasue; H Kohno; Y C Chang; H Taniura; A Yamanoi; M Uchida; T Kimoto; Y Takemoto; T Nakamura; H Yukaya
Journal:  Ann Surg       Date:  1993-04       Impact factor: 12.969

9.  Mutation pattern of the p53 gene as a diagnostic marker for multiple hepatocellular carcinoma.

Authors:  T Oda; H Tsuda; A Scarpa; M Sakamoto; S Hirohashi
Journal:  Cancer Res       Date:  1992-07-01       Impact factor: 12.701

10.  Identification and screening of 416 patients with chronic hepatitis at high risk to develop hepatocellular cancer.

Authors:  S A Curley; F Izzo; A Gallipoli; M de Bellis; F Cremona; V Parisi
Journal:  Ann Surg       Date:  1995-09       Impact factor: 12.969

View more
  34 in total

1.  Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications.

Authors:  Nazario Portolani; Arianna Coniglio; Sara Ghidoni; Mara Giovanelli; Anna Benetti; Guido Alberto Massimo Tiberio; Stefano Maria Giulini
Journal:  Ann Surg       Date:  2006-02       Impact factor: 12.969

2.  Actual 10-year survival following hepatectomy for hepatocellular carcinoma.

Authors:  Bernardo Franssen; Ghalib Jibara; Parissa Tabrizian; Myron E Schwartz; Sasan Roayaie
Journal:  HPB (Oxford)       Date:  2013-12-24       Impact factor: 3.647

3.  Prevention of cancer recurrence after treatment for hepatitis C virus-related hepatocellular carcinoma by interferon therapy.

Authors:  Shoji Kubo
Journal:  Clin J Gastroenterol       Date:  2009-04-08

4.  Risk factors of post-operative recurrence and adequate surgical approach to improve long-term outcomes of hepatocellular carcinoma.

Authors:  Junichi Shindoh; Kiyoshi Hasegawa; Yosuke Inoue; Takeaki Ishizawa; Rihito Nagata; Taku Aoki; Yoshihiro Sakamoto; Yasuhiko Sugawara; Masatoshi Makuuchi; Norihiro Kokudo
Journal:  HPB (Oxford)       Date:  2012-08-26       Impact factor: 3.647

5.  Outcome of 67 patients with hepatocellular cancer detected during screening of 1125 patients with chronic hepatitis.

Authors:  F Izzo; F Cremona; F Ruffolo; R Palaia; V Parisi; S A Curley
Journal:  Ann Surg       Date:  1998-04       Impact factor: 12.969

6.  Serum interleukin-10 but not interleukin-6 is related to clinical outcome in patients with resectable hepatocellular carcinoma.

Authors:  G Y Chau; C W Wu; W Y Lui; T J Chang; H L Kao; L H Wu; K L King; C C Loong; C Y Hsia; C W Chi
Journal:  Ann Surg       Date:  2000-04       Impact factor: 12.969

7.  Liver resection for hepatocellular carcinoma on cirrhosis: univariate and multivariate analysis of risk factors for intrahepatic recurrence.

Authors:  Giorgio Ercolani; Gian Luca Grazi; Matteo Ravaioli; Massimo Del Gaudio; Andrea Gardini; Matteo Cescon; Giovanni Varotti; Francesco Cetta; Antonino Cavallari
Journal:  Ann Surg       Date:  2003-04       Impact factor: 12.969

8.  Partial hepatectomy with wide versus narrow resection margin for solitary hepatocellular carcinoma: a prospective randomized trial.

Authors:  Ming Shi; Rong-Ping Guo; Xiao-Jun Lin; Ya-Qi Zhang; Min-Shan Chen; Chang-Qing Zhang; Wan Yee Lau; Jin-Qing Li
Journal:  Ann Surg       Date:  2007-01       Impact factor: 12.969

9.  Upregulation of nuclear PA28γ expression in cirrhosis and hepatocellular carcinoma.

Authors:  Motoi Kondo; Kohji Moriishi; Hiroshi Wada; Takehiro Noda; Shigeru Marubashi; Kenichi Wakasa; Yoshiharu Matsuura; Yuichiro Doki; Masaki Mori; Hiroaki Nagano
Journal:  Exp Ther Med       Date:  2011-12-14       Impact factor: 2.447

10.  Surgical management of early-stage hepatocellular carcinoma: resection or transplantation?

Authors:  Emily C Bellavance; Kimberly M Lumpkins; Gilles Mentha; Hugo P Marques; Lorenzo Capussotti; Carlo Pulitano; Pietro Majno; Paulo Mira; Laura Rubbia-Brandt; Alessandro Ferrero; Luca Aldrighetti; Steven Cunningham; Nadia Russolillo; Benjamin Philosophe; Eduardo Barroso; Timothy M Pawlik
Journal:  J Gastrointest Surg       Date:  2008-08-15       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.